<author><surname>Feshchenko</surname> <given-names>YuI</given-names> </author><author><surname>Melnyk</surname> <given-names>VM</given-names> </author><author><surname>Novozhilova</surname> <given-names>IO</given-names> </author><author><surname>Lyrnyk</surname> <given-names>SV</given-names> </author><title>The mortality of patients with tuberculosis: structure, dynamics and peculiarities in epidemic period</title><source>Ukr Pulmonol J</source><year>2009</year><volume>3</volume><fpage>5</fpage><lpage>9</lpage>
<author><surname>Nikolayevskyy</surname> <given-names>VV</given-names> </author><author><surname>Brown</surname> <given-names>TJ</given-names> </author><author><surname>Bazhora</surname> <given-names>YI</given-names> </author><author><surname>Asmolov</surname> <given-names>AA</given-names> </author><author><surname>Balabanova</surname> <given-names>YM</given-names> </author><author><surname>Drobniewski</surname> <given-names>FA</given-names> </author><title>Molecular epidemiology and prevalence of mutations conferring rifampicin and isoniazid resistance in Mycobacterium tuberculosis strains from the southern Ukraine</title><source>Clin Microbiol Infect</source><year>2007</year><volume>13</volume><fpage>129</fpage><lpage>138</lpage>
<author><surname>Atun</surname> <given-names>R</given-names> </author><author><surname>Olynik</surname> <given-names>I</given-names> </author><title>Resistance to implementing policy change: the case of Ukraine</title><source>Bulletin of World Health Organization</source><year>2008</year><volume>86</volume><fpage>147</fpage><lpage>154</lpage>
<author><surname>Batdelger</surname> <given-names>D</given-names> </author><author><surname>Dandii</surname> <given-names>D</given-names> </author><author><surname>Jirathitikal</surname> <given-names>V</given-names> </author><author><surname>Bourinbaiar</surname> <given-names>AS</given-names> </author><title>Open label trial of therapeutic hepatitis B vaccine V-5 Immunitor (V5) delivered by oral route</title><source>Lett Drug Design Discovery</source><year>2007</year><volume>4</volume><fpage>540</fpage><lpage>544</lpage>
<author><surname>Batdelger</surname> <given-names>D</given-names> </author><author><surname>Dandii</surname> <given-names>D</given-names> </author><author><surname>Jirathitikal</surname> <given-names>V</given-names> </author><author><surname>Bourinbaiar</surname> <given-names>AS</given-names> </author><title>Open label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C</title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>2733</fpage><lpage>2737</lpage>
<author><surname>Batdelger</surname> <given-names>D</given-names> </author><author><surname>Dandii</surname> <given-names>D</given-names> </author><author><surname>Dahgwahdorj</surname> <given-names>Ya</given-names> </author><author><surname>Erdenetsogt</surname> <given-names>E</given-names> </author><author><surname>Oyunbileg</surname> <given-names>J</given-names> </author><author><surname>Tsend</surname> <given-names>N</given-names> </author><author><surname>Bayarmagnai</surname> <given-names>B</given-names> </author><author><surname>Jirathitikal</surname> <given-names>V</given-names> </author><author><surname>Bourinbaiar</surname> <given-names>AS</given-names> </author><title>Clinical experience with therapeutic vaccines designed for patients with hepatitis</title><source>Curr Pharm Design</source><year>2009</year><volume>15</volume><fpage>1159</fpage><lpage>1171</lpage>
<author><surname>Arjanova</surname> <given-names>OV</given-names> </author><author><surname>Prihoda</surname> <given-names>ND</given-names> </author><author><surname>Yurchenko</surname> <given-names>LV</given-names> </author><author><surname>Sokolenko</surname> <given-names>NI</given-names> </author><author><surname>Frolov</surname> <given-names>VM</given-names> </author><author><surname>Tarakanovskaya</surname> <given-names>MG</given-names> </author><author><surname>Jirathitikal</surname> <given-names>V</given-names> </author><author><surname>Bourinbaiar</surname> <given-names>AS</given-names> </author><title>Phase 2 trial of V-5 Immunitor (V5) in patients with chronic hepatitis C co-infected with HIV and Mycobacterium tuberculosis</title><source>J Vaccin Vaccinat</source><year>2010</year><volume>1</volume><fpage>103</fpage>
<author><surname>Arjanova</surname> <given-names>OV</given-names> </author><author><surname>Prihoda</surname> <given-names>ND</given-names> </author><author><surname>Yurchenko</surname> <given-names>LV</given-names> </author><author><surname>Sokolenko</surname> <given-names>NI</given-names> </author><author><surname>Frolov</surname> <given-names>VM</given-names> </author><author><surname>Tarakanovskaya</surname> <given-names>MG</given-names> </author><author><surname>Batdelger</surname> <given-names>D</given-names> </author><author><surname>Jirathitikal</surname> <given-names>V</given-names> </author><author><surname>Bourinbaiar</surname> <given-names>AS</given-names> </author><title>Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV co-infected TB</title><source>Immunotherapy</source> in press
<author><surname>Reitman</surname> <given-names>S</given-names> </author><author><surname>Frankel</surname> <given-names>S</given-names> </author><title>A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases</title><source>Am J Clin Pathol</source><year>1957</year><volume>28</volume><fpage>56</fpage><lpage>63</lpage>
<author><surname>Ostrovski&#301;</surname> <given-names>VK</given-names> </author><author><surname>Asanov</surname> <given-names>BM</given-names> </author><author><surname>Iangolenko</surname> <given-names>DV</given-names> </author><title>Some blood indices and the leukocytic index of intoxication in tuberculosis, pneumonias, abscesses, and cancer of the lung</title><source>Probl Tuberk Bolezn Legk</source><year>2005</year><volume>3</volume><fpage>43</fpage><lpage>46</lpage>
<author><surname>Zaitzeva</surname> <given-names>SI</given-names> </author><author><surname>Matveeva</surname> <given-names>SL</given-names> </author><author><surname>Gerasimova</surname> <given-names>TG</given-names> </author><author><surname>Pashkov</surname> <given-names>YN</given-names> </author><author><surname>Butov</surname> <given-names>DA</given-names> </author><author><surname>Pylypchuk</surname> <given-names>VS</given-names> </author><author><surname>Frolov</surname> <given-names>VM</given-names> </author><author><surname>Kutsyna</surname> <given-names>GA</given-names> </author><title>Treatment of cavitary and infiltrating pulmonary tuberculosis with and without the immunomodulator Dzherelo</title><source>Clin Microbiol Infect</source><year>2009</year><volume>15</volume><fpage>1154</fpage><lpage>1162</lpage>
<author><surname>Veenstra</surname> <given-names>H</given-names> </author><author><surname>Baumann</surname> <given-names>R</given-names> </author><author><surname>Carroll</surname> <given-names>NM</given-names> </author><author><surname>Lukey</surname> <given-names>PT</given-names> </author><author><surname>Kidd</surname> <given-names>M</given-names> </author><author><surname>Beyers</surname> <given-names>N</given-names> </author><author><surname>Bolliger</surname> <given-names>CT</given-names> </author><author><surname>van Helden</surname> <given-names>PD</given-names> </author><author><surname>Walzl</surname> <given-names>G</given-names> </author><title>Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders</title><source>Clin Exp Immunol</source><year>2006</year><volume>145</volume><fpage>252</fpage><lpage>260</lpage>
<author><surname>Saukkonen</surname> <given-names>JJ</given-names> </author><author><surname>Cohn</surname> <given-names>DL</given-names> </author><author><surname>Jasmer</surname> <given-names>RM</given-names> </author><author><surname>Schenker</surname> <given-names>S</given-names> </author><author><surname>Jereb</surname> <given-names>JA</given-names> </author><author><surname>Nolan</surname> <given-names>CM</given-names> </author><author><surname>Peloquin</surname> <given-names>CA</given-names> </author><author><surname>Gordin</surname> <given-names>FM</given-names> </author><author><surname>Nunes</surname> <given-names>D</given-names> </author><author><surname>Strader</surname> <given-names>DB</given-names> </author><author><surname>Bernardo</surname> <given-names>J</given-names> </author><author><surname>Venkataramanan</surname> <given-names>R</given-names> </author><author><surname>Sterling</surname> <given-names>TR</given-names> </author>ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee<title>An official ATS statement: hepatotoxicity of antituberculosis therapy</title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>174</volume><fpage>935</fpage><lpage>952</lpage>
<author><surname>Vasantha</surname> <given-names>M</given-names> </author><author><surname>Gopi</surname> <given-names>PG</given-names> </author><author><surname>Subramani</surname> <given-names>R</given-names> </author><title>Weight gain in patients with tuberculosis treated under directly observed treatment short-course (DOTS)</title><source>Indian J Tuberc</source><year>2009</year><volume>56</volume><fpage>5</fpage><lpage>9</lpage>
<author><surname>Yew</surname> <given-names>WW</given-names> </author><author><surname>Leung</surname> <given-names>CC</given-names> </author><title>Prognostic significance of early weight gain in underweight patients with tuberculosis</title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>174</volume><fpage>236</fpage><lpage>237</lpage>
<author><surname>Majumdar</surname> <given-names>A</given-names> </author><author><surname>Kamble</surname> <given-names>PD</given-names> </author><author><surname>Harinath</surname> <given-names>BC</given-names> </author><title>Detection of circulating free and immune-complexed antigen in pulmonary tuberculosis using cocktail of antibodies to Mycobacterium tuberculosis excretory secretory antigens by peroxidase enzyme immunoassay</title><source>Indian J Tuberc</source><year>2010</year><volume>57</volume><fpage>67</fpage><lpage>74</lpage>
<author><surname>Vilaplana</surname> <given-names>C</given-names> </author><author><surname>Montan&#233;</surname> <given-names>E</given-names> </author><author><surname>Pinto</surname> <given-names>S</given-names> </author><author><surname>Barriocanal</surname> <given-names>AM</given-names> </author><author><surname>Domenech</surname> <given-names>G</given-names> </author><author><surname>Torres</surname> <given-names>F</given-names> </author><author><surname>Cardona</surname> <given-names>PJ</given-names> </author><author><surname>Costa</surname> <given-names>J</given-names> </author><title>Double-blind, randomized, placebo-controlled Phase I clinical trial of the therapeutical antituberculous vaccine RUTI</title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>1106</fpage><lpage>1116</lpage>
<author><surname>Stanford</surname> <given-names>J</given-names> </author><author><surname>Stanford</surname> <given-names>C</given-names> </author><author><surname>Grange</surname> <given-names>J</given-names> </author><title>Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis</title><source>Front Biosci</source><year>2004</year><volume>9</volume><fpage>1701</fpage><lpage>1719</lpage>
<author><surname>Zhao</surname> <given-names>G-R</given-names> </author><author><surname>Feng</surname> <given-names>D-H</given-names> </author><title>A systematic review of inactivated Mycobacterium phlei injection for adjunctive treatment of drug resistant pulmonary tuberculosis</title><source>Pharm J Chin PLA</source><year>2009</year><volume>25</volume><fpage>361</fpage><lpage>364</lpage>
<author><surname>Nyasulu</surname> <given-names>PS</given-names> </author><title>Role of adjunctive Mycobacterium w immunotherapy for tuberculosis</title><source>J Exp Clin Med</source><year>2010</year><volume>2</volume><fpage>123</fpage><lpage>129</lpage>
<author><surname>Svistunova</surname> <given-names>AS</given-names> </author><author><surname>Pinegin</surname> <given-names>BV</given-names> </author><author><surname>Selitskaia</surname> <given-names>RP</given-names> </author><author><surname>Arshinova</surname> <given-names>SS</given-names> </author><author><surname>Klimova</surname> <given-names>EG</given-names> </author><author><surname>Andronova</surname> <given-names>TM</given-names> </author><author><surname>Batyrov</surname> <given-names>FA</given-names> </author><author><surname>Simonova</surname> <given-names>AV</given-names> </author><title>The use of immunomodulator likopid in the combined treatment pulmonary tuberculosis</title><source>Probl Tuberk</source><year>2002</year><volume>3</volume><fpage>21</fpage><lpage>25</lpage>
<author><surname>Lei</surname> <given-names>JP</given-names> </author><author><surname>Xiong</surname> <given-names>GL</given-names> </author><author><surname>Hu</surname> <given-names>QF</given-names> </author><author><surname>Li</surname> <given-names>Y</given-names> </author><author><surname>Zong</surname> <given-names>PL</given-names> </author><author><surname>Tu</surname> <given-names>SH</given-names> </author><author><surname>Tu</surname> <given-names>RY</given-names> </author><title>Immunotherapeutic efficacy of BCG vaccine in pulmonary tuberculosis and its preventive effect on multidrug-resistant tuberculosis</title><source>Zhonghua Yu Fang Yi Xue Za Zhi</source><year>2008</year><volume>42</volume><fpage>86</fpage><lpage>89</lpage>
<author><surname>Kaufmann</surname> <given-names>SH</given-names> </author><title>Is the development of a new tuberculosis vaccine possible?</title><source>Nat Med</source><year>2000</year><volume>6</volume><fpage>955</fpage><lpage>960</lpage>
<author><surname>Kato</surname> <given-names>S</given-names> </author><author><surname>Tokunaga</surname> <given-names>O</given-names> </author><author><surname>Yoshiyama</surname> <given-names>T</given-names> </author><title>Analysis of Koch's phenomenon by BCG vaccination with the multi-puncture method in Japan</title><source>Kekkaku</source><year>2010</year><volume>85</volume><fpage>782</fpage><lpage>785</lpage>
<author><surname>Repique</surname> <given-names>CJ</given-names> </author><author><surname>Li</surname> <given-names>A</given-names> </author><author><surname>Collins</surname> <given-names>FM</given-names> </author><author><surname>Morris</surname> <given-names>SL</given-names> </author><title>DNA Immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge</title><source>Infect Immun</source><year>2002</year><volume>70</volume><fpage>3318</fpage><lpage>3323</lpage>
<author><surname>Moreira</surname> <given-names>AL</given-names> </author><author><surname>Tsenova</surname> <given-names>L</given-names> </author><author><surname>Aman</surname> <given-names>MH</given-names> </author><author><surname>Bekker</surname> <given-names>L-G</given-names> </author><author><surname>Freeman</surname> <given-names>S</given-names> </author><author><surname>Mangaliso</surname> <given-names>B</given-names> </author><author><surname>Schr&#246;der</surname> <given-names>U</given-names> </author><author><surname>Jagirdar</surname> <given-names>J</given-names> </author><author><surname>Rom</surname> <given-names>WN</given-names> </author><author><surname>Tovey</surname> <given-names>MG</given-names> </author><author><surname>Freedman</surname> <given-names>VH</given-names> </author><author><surname>Kaplan</surname> <given-names>G</given-names> </author><title>Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice</title><source>Infect Immun</source><year>2002</year><volume>70</volume><fpage>2100</fpage><lpage>2107</lpage>
<author><surname>Basaraba</surname> <given-names>RJ</given-names> </author><author><surname>Izzo</surname> <given-names>AA</given-names> </author><author><surname>Brandt</surname> <given-names>L</given-names> </author><author><surname>Orme</surname> <given-names>IM</given-names> </author><title>Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations</title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>280</fpage><lpage>286</lpage>
<author><surname>Radaeva</surname> <given-names>TV</given-names> </author><author><surname>Nikonenko</surname> <given-names>BV</given-names> </author><author><surname>Kapina</surname> <given-names>MA</given-names> </author><author><surname>Mishchenko</surname> <given-names>VV</given-names> </author><author><surname>Apt</surname> <given-names>AS</given-names> </author><title>Experimental approaches to designing vaccines against tuberculous infection reactivation</title><source>Probl Tuberk Bolezn Legk</source><year>2006</year><volume>5</volume><fpage>45</fpage><lpage>48</lpage>
<author><surname>Cruz</surname> <given-names>A</given-names> </author><author><surname>Fraga</surname> <given-names>AG</given-names> </author><author><surname>Fountain</surname> <given-names>JJ</given-names> </author><author><surname>Rangel-Moreno</surname> <given-names>J</given-names> </author><author><surname>Torrado</surname> <given-names>E</given-names> </author><author><surname>Saraiva</surname> <given-names>M</given-names> </author><author><surname>Pereira</surname> <given-names>DR</given-names> </author><author><surname>Randall</surname> <given-names>TD</given-names> </author><author><surname>Pedrosa</surname> <given-names>J</given-names> </author><author><surname>Cooper</surname> <given-names>AM</given-names> </author><author><surname>Castro</surname> <given-names>AG</given-names> </author><title>Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis</title><source>J Exp Med</source><year>2010</year><volume>207</volume><fpage>1609</fpage><lpage>1616</lpage>
<author><surname>Derrick</surname> <given-names>SC</given-names> </author><author><surname>Perera</surname> <given-names>LP</given-names> </author><author><surname>Dheenadhayalan</surname> <given-names>V</given-names> </author><author><surname>Yang</surname> <given-names>A</given-names> </author><author><surname>Kolibab</surname> <given-names>K</given-names> </author><author><surname>Morris</surname> <given-names>SL</given-names> </author><title>The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis</title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>6092</fpage><lpage>6098</lpage>
<author><surname>Roth</surname> <given-names>AE</given-names> </author><author><surname>Benn</surname> <given-names>CS</given-names> </author><author><surname>Ravn</surname> <given-names>H</given-names> </author><author><surname>Rodrigues</surname> <given-names>A</given-names> </author><author><surname>Lisse</surname> <given-names>IM</given-names> </author><author><surname>Yazdanbakhsh</surname> <given-names>M</given-names> </author><author><surname>Whittle</surname> <given-names>H</given-names> </author><author><surname>Aaby</surname> <given-names>P</given-names> </author><title>Effect of revaccination with BCG in early childhood on mortality: randomised trial in Guinea-Bissau</title><source>BMJ</source><year>2010</year><volume>340</volume><fpage>c671</fpage>
<author><surname>Silin</surname> <given-names>DS</given-names> </author><author><surname>Lyubomska</surname> <given-names>OV</given-names> </author><author><surname>Jirathitikal</surname> <given-names>V</given-names> </author><author><surname>Bourinbaiar</surname> <given-names>AS</given-names> </author><title>Oral vaccination: where we are?</title><source>Expert Opin Drug Deliv</source><year>2007</year><volume>4</volume><fpage>323</fpage><lpage>340</lpage>
<author><surname>Zaitzeva</surname> <given-names>SI</given-names> </author><author><surname>Matveeva</surname> <given-names>SL</given-names> </author><author><surname>Gerasimova</surname> <given-names>TG</given-names> </author><author><surname>Pashkov</surname> <given-names>YuN</given-names> </author><author><surname>Butov</surname> <given-names>DA</given-names> </author><author><surname>Pylypchuk</surname> <given-names>VS</given-names> </author><author><surname>Frolov</surname> <given-names>VM</given-names> </author><author><surname>Kutsyna</surname> <given-names>GA</given-names> </author><title>Efficacy and safety of phytoconcentrate Dzherelo (Immunoxel) in treatment of patients with multi-drug resistant TB (MDR-TB) in comparison to standard chemotherapy</title><source>Res J Med Sci</source><year>2009</year><volume>3</volume><fpage>36</fpage><lpage>41</lpage>
<author><surname>Churchyard</surname> <given-names>GJ</given-names> </author><author><surname>Kaplan</surname> <given-names>G</given-names> </author><author><surname>Fallows</surname> <given-names>D</given-names> </author><author><surname>Wallis</surname> <given-names>RS</given-names> </author><author><surname>Onyebujoh</surname> <given-names>P</given-names> </author><author><surname>Rook</surname> <given-names>GA</given-names> </author><title>Advances in immunotherapy for tuberculosis treatment</title><source>Clin Chest Med</source><year>2009</year><volume>30</volume><fpage>769</fpage><lpage>782</lpage>
<author><surname>Thaiss</surname> <given-names>CA</given-names> </author><author><surname>Kaufmann</surname> <given-names>SH</given-names> </author><title>Toward novel vaccines against tuberculosis: current hopes and obstacles</title><source>Yale J Biol Med</source><year>2010</year><volume>83</volume><fpage>209</fpage><lpage>215</lpage>
<author><surname>Dheda</surname> <given-names>K</given-names> </author><author><surname>Schwander</surname> <given-names>SK</given-names> </author><author><surname>Zhu</surname> <given-names>B</given-names> </author><author><surname>van Zyl-Smit</surname> <given-names>RN</given-names> </author><author><surname>Zhang</surname> <given-names>Y</given-names> </author><title>The immunology of tuberculosis: from bench to bedside</title><source>Respirology</source><year>2010</year><volume>15</volume><fpage>433</fpage><lpage>450</lpage>